Dermatomyositis

• 

  Subject Areas on Research

  • 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. 
  • 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. 
  • 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. 
  • 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. 
  • A Rare Manifestation of a Rare Disease: The Importance of Thinking Outside the Box in a Patient With Complex Dermatomyositis. 
  • Abnormalities in serum osteocalcin values in children with chronic rheumatic diseases. 
  • Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. 
  • An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. 
  • Analysis of HLA-DM polymorphism in juvenile dermatomyositis (JDM) patients. 
  • Association of Short-Term Ultraviolet Radiation Exposure and Disease Severity in Juvenile Dermatomyositis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. 
  • Association of the HLA-DQA1*0501 allele in multiple racial groups with juvenile dermatomyositis. 
  • Association with HLA-DRβ1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis. 
  • Avascular necrosis of the metacarpals in juvenile dermatomyositis. 
  • Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry. 
  • Biologic predictors of clinical improvement in rituximab-treated refractory myositis. 
  • Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. 
  • Cardiovascular Health in Pediatric Rheumatologic Diseases. 
  • Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample. 
  • Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. 
  • Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash. 
  • Chimerism in children with juvenile dermatomyositis. 
  • Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. 
  • Comparison of Patient-Reported Outcomes Measurement Information System Computerized Adaptive Testing Versus Fixed Short Forms in Juvenile Myositis. 
  • Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. 
  • Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. 
  • Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. 
  • Dendritic cells and the immunopathogenesis of idiopathic inflammatory myopathies. 
  • Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. 
  • Dermatomyositis associated with IgA deposition. 
  • Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. 
  • Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. 
  • Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule. 
  • Disease activity, proteinuria, and vitamin D status in children with systemic lupus erythematosus and juvenile dermatomyositis. 
  • Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis? 
  • Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. 
  • Engaging patients and parents to improve mental health intervention for youth with rheumatological disease. 
  • Enzyme elevation in patients with juvenile dermatomyositis and steroid myopathy. 
  • Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. 
  • Familial dermatomyositis. 
  • Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis. 
  • Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. 
  • Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. 
  • History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. 
  • Immunogenetic associations in childhood dermatomyositis. 
  • Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. 
  • Immunogenetic studies in families of children with juvenile dermatomyositis. 
  • Immunological biomarkers in dermatomyositis. 
  • Immunopathogenesis of juvenile dermatomyositis. 
  • Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis. 
  • Inpatient burden of juvenile dermatomyositis among children in the United States. 
  • Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. 
  • Juvenile Dermatomyositis and Development of Malignancy: 2 Case Reports and a Literature Review. 
  • Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. 
  • Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. 
  • Juvenile dermatomyositis: recognition and treatment. 
  • Longitudinal peripheral blood lymphocyte subsets correlate with decreased disease activity in juvenile dermatomyositis. 
  • Metabolomics analysis identifies a lipidomic profile in treatment-naïve juvenile dermatomyositis patients vs healthy control subjects. 
  • Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501. 
  • Panniculitis in juvenile dermatomyositis. 
  • Parent Perspectives on Addressing Emotional Health for Children and Young Adults With Juvenile Myositis. 
  • Pathogenesis of myositis in children. 
  • Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry. 
  • Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia. 
  • Pilot Study of the Juvenile Dermatomyositis Consensus Treatment Plans: A CARRA Registry Study. 
  • Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. 
  • Predictors of Hospitalization, Length of Stay, and Cost of Care Among Adults With Dermatomyositis in the United States. 
  • Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry. 
  • Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. 
  • Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. 
  • Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. 
  • Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. 
  • Quantitative EMG in inflammatory myopathy. 
  • Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. 
  • Recent advances in juvenile dermatomyositis. 
  • Rheumatologic manifestations of cancer. 
  • Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. 
  • Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. 
  • T-cell transcriptomics from peripheral blood highlights differences between polymyositis and dermatomyositis patients. 
  • The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. 
  • The Myositis Activities Profile -- initial validation for assessment of polymyositis/dermatomyositis in the USA. 
  • The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. 
  • The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. 
  • Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. 
  • Type I interferon pathway in adult and juvenile dermatomyositis. 
  • Validation of International Classification of Diseases Codes for the Epidemiologic Study of Dermatomyositis. 
  • Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. 
• 

  Keywords of People

  • Ardalan, Kaveh, Assistant Professor of Pediatrics, Pediatrics, Rheumatology
  • Gonzalez, Natalia Laura, Assistant Professor of Neurology, Neurology, Neuromuscular Disease
  • Hall III, Russell P., J. Lamar Callaway Distinguished Professor of Dermatology, in the School of Medicine, Integrative Immunobiology